Nurix Therapeutics Inc
NASDAQ:NRIX
Nurix Therapeutics Inc
NASDAQ:NRIX
Price:
15.58 USD
3.11%
Market Closed
Updated:
Jun 1, 2024
P/E
Price to Earnings
Price to Earnings
-6.4
Current
-5.1
Median
24.7
Industry
Lower
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-6.4
Market Cap
/
923.9m
Net Income
-144.7m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Nurix Therapeutics Inc
NASDAQ:NRIX
|
923.9m USD | -6.4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
284.7B USD | 47.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
164.1B USD | 43.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.6B USD | 29.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.6B USD | 27.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.3B AUD | 36.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
79.8B USD | 164.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
54.6B USD | -9.1 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.7B USD | 28 | |
| IE |
|
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 60.8 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-5.3
2-Years Forward
P/E
-4.9
3-Years Forward
P/E
-4.6
You don't have any saved screeners yet
